RxDoctor Payments Data

Damian Brezinski, MD

Interventional Cardiology · Carolina Beach, NCNPI 1740395029

Payments from drug & device makers

$4,097in general payments, 2019–2025

Across 237 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$907
  • Novartis$650
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$387
  • Irhythm Technologies, Inc.$304
  • Amarin Pharma, Inc.$209
  • Regeneron Healthcare Solutions, Inc.$180
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,07399%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,097 in reported general payments places this provider in the 25th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$245,420
Medicare patients
210
Services billed
2,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab114$169,029
EliquisApixaban50$54,600
XareltoRivaroxaban40$45,951
Praluent PenAlirocumab40$41,310
OzempicSemaglutide25$24,775
Clonidine55$9,852
Ranolazine ErRanolazine49$4,074
Metoprolol Succinate97$1,256
Dofetilide13$1,193
Prasugrel Hcl11$1,109
Albuterol Sulfate HfaAlbuterol Sulfate21$915
ClopidogrelClopidogrel Bisulfate96$865
Atorvastatin Calcium74$837
Atenolol148$806
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$54,60050 claims
Johnson & JohnsonXarelto$123$45,95140 claims
Novo NordiskOzempic$93$24,77525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Carolina Beach

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →